Cochrane · systematic review · CD008037
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
Hurley, MN, Smith, S, Forrester, DL, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
19
No studies
16
Included studies
NR
No studies 16 · 45.7%Ungraded 0 · 0%Very low 7 · 20%Low 7 · 20%Moderate 5 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis
Population: children and adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary exacerbations Days of antibiotic use Summary of findings: β‐carotene vs placebo | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Respiratory function absolute FEV1 % predicted Summary of findings: β‐carotene vs placebo | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Summary of findings: β‐carotene vs placebo | no estimate extracted | 1 study · 24 participants | Low Downgraded: risk of bias, imprecision |
Need for antibiotics see pulmonary exacerbations Summary of findings: β‐carotene vs placebo | no estimate extracted | NR | No studies |
QoL Summary of findings: β‐carotene vs placebo | no estimate extracted | NR | No studies |
Sputum microbiology Summary of findings: β‐carotene vs placebo | no estimate extracted | NR | No studies |
Inflammatory markers Summary of findings: β‐carotene vs placebo | no estimate extracted | NR | No studies |
Summary of findings: garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis
Population: children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary exacerbations Summary of findings: garlic supplementation vs placebo | no estimate extracted | NR | No studies |
Respiratory function change from baseline in % predicted FEV1 Summary of findings: garlic supplementation vs placebo | MD 1.59 | 1 study · 26 participants | Moderate Downgraded: imprecision |
Adverse events mild adverse events Summary of findings: garlic supplementation vs placebo | no estimate extracted | 1 study · 26 participants | Moderate Downgraded: imprecision |
Need for antibiotics days of antibiotic use Summary of findings: garlic supplementation vs placebo | no estimate extracted | NR | No studies |
QoL Summary of findings: garlic supplementation vs placebo | no estimate extracted | NR | No studies |
Sputum microbiology Summary of findings: garlic supplementation vs placebo | no estimate extracted | NR | No studies |
Inflammatory markers Summary of findings: garlic supplementation vs placebo | no estimate extracted | NR | No studies |
Summary of findings: monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis
Population: children (12 or over) and adults with cystic fibrosis and lung infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary exacerbations Summary of findings: monoclonal antibody KB001‐A vs placebo | RR 0.25 [0.03, 2.4] | 2 studies · 196 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) Summary of findings: monoclonal antibody KB001‐A vs placebo | RR 4.74 [0.28, 79.44] | 2 studies · 196 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events number of participants experiencing adverse events Summary of findings: monoclonal antibody KB001‐A vs placebo | RR 1.3 [0.9, 1.87] | 2 studies · 196 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Need for antibiotics time to need for antibiotics Summary of findings: monoclonal antibody KB001‐A vs placebo | HR 1 [0.69, 1.45] | 1 study · 169 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
QoL change in CFQ‐R score Summary of findings: monoclonal antibody KB001‐A vs placebo | no estimate extracted | 1 study · 27 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Sputum microbiology Summary of findings: monoclonal antibody KB001‐A vs placebo | no estimate extracted | 1 study · 27 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Inflammatory markers Summary of findings: monoclonal antibody KB001‐A vs placebo | no estimate extracted | 2 studies · 196 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings: nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis
Population: children (12 or over) and young adults with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary exacerbations Summary of findings: nitric oxide vs placebo | no estimate extracted | NR | No studies |
Respiratory function mean change in FEV1 % predicted from baseline Summary of findings: nitric oxide vs placebo | no estimate extracted | 1 study · 12 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Summary of findings: nitric oxide vs placebo | no estimate extracted | 2 studies · 30 participants | Very low Downgraded: risk of bias, imprecision |
Need for antibiotics Summary of findings: nitric oxide vs placebo | no estimate extracted | NR | No studies |
QoL Summary of findings: nitric oxide vs placebo | no estimate extracted | NR | No studies |
Sputum microbiology Summary of findings: nitric oxide vs placebo | no estimate extracted | 2 studies · 30 participants | Very low Downgraded: risk of bias, imprecision |
Inflammatory markers Summary of findings: nitric oxide vs placebo | no estimate extracted | NR | No studies |
Summary of findings: Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis
Population: children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary exacerbations number of participants requiring IV antibiotics Summary of findings: Zinc supplementation vs placebo | RR 1.85 [0.65, 5.26] | 1 study · 37 participants | Moderate Downgraded: imprecision |
Respiratory function mean FEV1 % predicted Summary of findings: Zinc supplementation vs placebo | no estimate extracted | 2 studies · 62 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events number of participants hospitalised during the trial Summary of findings: Zinc supplementation vs placebo | RR 1.23 [0.51, 2.97] | 1 study · 37 participants | Moderate Downgraded: imprecision |
Need for antibiotics number of days on IV or oral antibiotics Summary of findings: Zinc supplementation vs placebo | MD 0.52 | 2 studies · 62 participants | Very low Downgraded: risk of bias, imprecision |
QoL Summary of findings: Zinc supplementation vs placebo | no estimate extracted | NR | No studies |
Sputum microbiology Summary of findings: Zinc supplementation vs placebo | no estimate extracted | NR | No studies |
Inflammatory markers Summary of findings: Zinc supplementation vs placebo | no estimate extracted | NR | No studies |